Trajectories of Function and Symptom Change in Desvenlafaxine Clinical Trials: Toward Personalized Treatment for Depression.

ABSTRACT:

Purpose/background

Heterogeneity has been documented in trajectories of symptom change during antidepressant treatment for major depressive disorder (MDD). It is unclear whether distinct trajectories of change exist for functioning during antidepressant treatment.

Methods/procedures

This analysis explored distinct trajectories of functioning in MDD and tested whether they corresponded to trajectories of symptom change. Data were from 4317 patients and were pooled from 9 randomized placebo-controlled trials. Growth mixture modeling was used to identify trajectories of Hamilton Rating Scale for Depression (HRSD) and Sheehan Disability Scale (SDS) for placebo- and desvenlafaxine-treated patients.

Findings/results

Three trajectories were identified for symptoms (HRSD) in

SUBMITTER: Zilcha-Mano S 

PROVIDER: S-EPMC8407446 | biostudies-literature | 2021 Sep-Oct 01

REPOSITORIES: biostudies-literature